Rapid Responses to:

EDITORIALS: Tristan Ferry and Jerome Etienne Community acquired MRSA in Europe BMJ 2007; 335: 947-948 [Full text]

Rapid Responses: Submit a response to this article

Rapid Responses published:

Lenozolid and Vancomycin in MRSA

H Khan Saeed, Mahmood Ahmad   (6 November 2007)

Lenozolid and Vancomycin in MRSA 6 November 2007
H Khan Saeed, F2 Medway Maritime Hospital, Gillingham,Kent, ME7 5NY, Mahmood Ahmad Send response to journal: Re: Lenozolid and Vancomycin in MRSA	Vancomycin has become the antibiotic most commonly used for MRSA endocarditis. However recently isolates of intermediate resistance to Vancomycin and 2 cases of high resistance isolates have been published. [1][2] Interest in Leniozolid an oxazolidinone with activity against Staphylococcus Aureus as an alternative to Vancomyin has been recently investigated in trials on rabbit heart endocarditis and the results of a paper recently published showed that Lenezolid is not as effective in reducing vegetations as Vancomycin. [3] In fact a combination of Vancomycin and Lenezolid was less effective than Vancomycin used alone. Lenezolid also produced a dose dependant myelosuppression.[4] [1]Miller, D., V. Urdaneta, A. Weltman, and S. Park. 2002. Public health dispatch: vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb. Mortal. Wkly. Rep. 51:902.[Medline] [2] Sievert, D. M., M. L. Boulton, G. Stoltman, D. Johnson, M. G. Stobierski, F. P. Downes, P. A. Somsel, J. T. Rudrik, W. Brown, W. Hafeez, T. Lundstrom, E. Flanagan, R. Johnson, J. Mitchell, and S. Chang. 2002. Staphylococcus aureus resistant to vancomycin. Morb. Mortal. Wkly. Rep. 51:565-567.[Medline] [3] Oramas-Shirey, M. P., L. V. Buchanan, C. L. Dileto-Fang, C. F. Dailey, C. W. Ford, D. H. Batts, and J. K. Gibson. 2001. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J. Antimicrob. Chemother. 47:349-352 [4] Gerson, S. L., S. L. Kaplan, J. B. Bruss, V. Le, F. M. Arellano, B. Hafkin, and D. J. Kuter. 2002. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46:2723-2726 Competing interests: None declared